Trump’s Budget BOMBSHELL: Cannabis Policy Reversed

(ProsperNews.net) – President Trump’s latest moves on medical marijuana deliver a stunning policy reversal, shielding state programs from federal overreach while fast-tracking research—yet leaving recreational users in the cold.

Story Highlights

Trump’s FY2027 budget retains the Rohrabacher-Blumenauer rider, protecting state-licensed medical marijuana from DOJ interference for the first time in his proposals.
December 2025 Executive Order accelerates marijuana rescheduling from Schedule I to Schedule III, recognizing medical uses based on HHS evidence.
Over 38 states gain federal non-interference, enabling patient access to treatments for pain, nausea, and anorexia without fear of raids.
Recreational sales in D.C. remain blocked, upholding federal prohibitions amid GOP control of Congress.

Trump’s Policy Pivot on Medical Cannabis

President Donald Trump submitted the Fiscal Year 2027 budget request in April 2026, proposing to retain the Rohrabacher-Blumenauer rider. This annual provision bars the Department of Justice from using funds to interfere with state medical marijuana laws. The budget lists protections for over 30 states and territories, plus a block on D.C. recreational sales. This marks a departure from Trump’s first-term budgets that sought to repeal the rider. States with licensed programs now face reduced federal risk, aligning with evidence-based reforms.

Executive Order Accelerates Rescheduling

On December 18, 2025, Trump signed the Executive Order “Increasing Medical Marijuana and Cannabidiol Research.” The order directs the Attorney General to expedite rescheduling marijuana to Schedule III under the Controlled Substances Act. HHS and FDA findings from 2023 cite medical utility for chemotherapy-induced nausea, pain, and anorexia. This follows a May 2024 DOJ proposed rule that drew 43,000 public comments. Schedule III status would acknowledge accepted medical use and moderate abuse potential, easing research barriers long blocked by Schedule I classification.

Unlike the 1970 Controlled Substances Act’s original Schedule I designation of no medical value, this shift corrects decades of misalignment with state laws. Trump’s first term rescinded Obama-era Cole Memo protections and opposed rider funding. Now, with Republican control of Congress, the administration proactively supports state autonomy while rejecting recreational expansion.

Stakeholders and Power Shifts

Key players include Trump, who balances medical access with anti-recreational enforcement, and Rep. Andy Harris (R-MD), who champions the D.C. sales block. HHS, FDA, and NIDA provided scientific backing for rescheduling. States operating 38+ medical programs seek non-interference to serve patients. Congress holds final say on budget riders, often overriding executive requests. This dynamic shows Trump aligning with congressional protections he once fought, reflecting voter priorities in cannabis-friendly states.

BREAKING: Trump admin loosens regulations on state-licensed medical marijuana, shifting it to a Schedule III drug instead of Schedule I pic.twitter.com/qUAMsbysFp

— Fox News (@FoxNews) April 23, 2026

Employers face potential changes as Schedule III enables FDA-approved prescriptions and insurance coverage, including Medicaid for qualifying conditions. Medical patients gain regulated access, reducing reliance on black markets. Cannabis firms see legitimacy for medical products, while recreational markets remain federally prohibited.

Impacts and Broader Significance

Short-term, rider passage prevents DOJ raids on state programs; the Executive Order speeds research models. Long-term, Schedule III opens doors to prescriptions, insurance reimbursements, and standardized hemp/CBD rules post-2018 Farm Bill. Economic growth follows from regulated markets and reduced patient costs. Socially, terminal illness sufferers benefit from proven therapies. Politically, this GOP evolution underscores limited federal overreach, resonating with Americans frustrated by elite-driven policies that ignore states’ rights and hard-working families’ needs. Both conservatives wary of government expansion and liberals seeking patient relief share distrust of D.C. failures—here, Trump delivers common-sense progress without full legalization chaos.